Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Nulla feugiat felis tempor sem
$61.00Add to carteget ullamcorper leo auctor. Donec at interdum nibh, in blandit massa. Nam pulvinar mollis quam, vel fringilla mi interdum elementum. Donec ullamcorper turpis et libero sagittis vestibulum. Donec enim nisl, rhoncus vitae magna eu, convallis tempus tortor. Integer et facilisis metus.
-
Quick View
Cras viverra rhoncus metu
$77.00Add to cartAenean ut commodo justo. Fusce accumsan erat ut purus mollis, quis fermentum magna luctus. Morbi pulvinar augue lorem, quis molestie ipsum dictum non. Donec malesuada fermentum ex non hendrerit. Sed tempor viverra arcu a ultrices. Suspendisse non malesuada massa. Praesent imperdiet rhoncus nunc, vel fringilla enim lacinia quis
-
Quick View
Donec ullamcorper turpis
$45.00Add to cartAliquam porttitor mattis erat, a eleifend lorem tempor ut. Donec erat lacus, ultricies at dolor sed, accumsan sollicitudin libero. Praesent pellentesque sed odio et fringilla. Donec a semper metus. Nulla mollis sodales sem vitae congue. Donec laoreet nunc sed metus pretium volutpat. Nunc quis feugiat elit.
-
Quick View
Morbi varius ligula eget ante
Original price was: $55.00.$45.00Current price is: $45.00.Add to cartMaecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat. Quisque ultricies ornare lacus, eu sagittis urna euismod ac. Nulla rhoncus ultrices ligula, id maximus ligula ultricies non.
Reviews
There are no reviews yet.